Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term

Globus Medical (GMED) carries a Zacks Rank #2 (Buy), a VGM Score of A and a Momentum Style Score of B; its shares gained 3.2% over the past four weeks. For fiscal 2026, one analyst raised their earnings estimate in the last 60 days, while the Zacks consensus estimate is $4.99 per share (the article reports an increase of $0.00). GMED's average earnings surprise is +27.9%.

Analysis

This is a sentiment signal, not a new fundamental catalyst. The key tension is that a single upward estimate revision has not moved consensus EPS: momentum screens may attract short-horizon flows, but they do not yet show broadening earnings conviction. The reported historical earnings-surprise average is backward-looking and does not establish that current estimates are conservative; verify the drivers and whether they recur before underwriting the multiple.

Over the next 1–3 months, the relevant test is whether upcoming results convert the screen-driven interest into stronger forward sales, procedure growth, and guidance. Over 6–18 months, the durable question is whether Globus Medical can sustain share gains and execute against established spinal/orthopedic device competitors such as Medtronic, Stryker, and Zimmer Biomet; the article supplies no comparative performance data. Integration and product execution are potential company-specific swing factors, but require verification rather than assumption.

Contrarian read: the “long-term” framing overstates what is essentially a short-horizon ranking argument. With consensus EPS unchanged, chasing a recent price move risks buying sentiment without estimate breadth. No valuation, current positioning, or price levels are provided, so risk/reward cannot be quantified; absent a confirming operating catalyst, the signal is watchlist-grade rather than a standalone long.

Key Decisions for Investors

• Do not initiate a momentum-chase position solely on the ranking article. Reassess after the next earnings release, focusing on forward revenue/guidance, procedure trends, and whether analyst estimate revisions broaden beyond one contributor.
• Keep GMED on an event-driven watchlist; consider a long only if operating results and forward estimates confirm improving fundamentals and the entry price offers acceptable valuation-adjusted upside.
• For a relative-value screen, compare GMED’s forward estimate revisions and operating trajectory with Medtronic, Stryker, and Zimmer Biomet before considering a pair; do not assume the article establishes relative outperformance.
• Falsification/stop condition for the bullish screen thesis: consensus estimates remain flat or turn down, or company guidance and reported operating trends fail to support the earnings-surprise history. Verify valuation and current positioning before sizing any trade.